AstraZeneca PLC (AZN) — Stock Price, Chart & Analysis
AstraZeneca PLC (AZN) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $261.12B and a trailing P/E ratio of 25.21. Over the past 52 weeks, AZN has traded between $145.80 and $212.71. AstraZeneca PLC pays a dividend yielding 1.9%. View the live AZN chart, technical opinion, analyst ratings, fundamentals and latest news below.
AstraZeneca PLC (AZN) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $261.12B |
| P/E ratio (TTM) | 25.21 |
| EPS (TTM) | $6.68 |
| Dividend yield | 1.9% |
| 52-week high | $212.71 |
| 52-week low | $145.80 |
| Beta | 0.20 |
| Avg. volume | 3.38M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about AstraZeneca PLC (AZN)
How much does one share of AstraZeneca PLC cost?
As of the latest update, one share of AstraZeneca PLC (AZN) trades at $100 (+0.00% today).
What is AstraZeneca PLC's market cap?
AstraZeneca PLC has a market capitalization of approximately $261.12B.
What is AstraZeneca PLC's P/E ratio?
AstraZeneca PLC has a trailing price-to-earnings (P/E) ratio of 25.21.
What is AstraZeneca PLC's earnings per share (EPS)?
AstraZeneca PLC's trailing twelve-month EPS is $6.68.
Does AstraZeneca PLC pay a dividend?
Yes — AstraZeneca PLC pays a dividend with a yield of 1.9% ($3.20 per share annually).
What is AstraZeneca PLC's 52-week trading range?
Over the past year, AZN has traded between $145.80 and $212.71.
What is the analyst price target for AstraZeneca PLC?
The mean analyst price target for AstraZeneca PLC is $212.17. This is informational only and not investment advice.
Latest AstraZeneca PLC (AZN) news
- AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’News · Sep 22, 2026
- Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to NoteNews · Sep 21, 2026
- Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?News · Sep 18, 2026
- AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III SuccessNews · Sep 18, 2026
- AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead OptimizationNews · Sep 22, 2026
- Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move FirstNews · Sep 22, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live AZN dashboard…